A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
REGULATORY
Rx-to-OTC Switching of Morning After Pills Needs Cautious Approach: Lawmakers
A league of Liberal Democratic Party (LDP) lawmakers on December 26 submitted a statement to the health minister, calling for a cautious approach to the switching of prescription emergency contraceptive pills to OTC status from the standpoint of ensuring their…
To read the full story
Related Article
- Purchasers Satisfied, Pharmacy Service “Appropriate” in Non-Prescription Pilot for Emergency Contraceptives
May 14, 2024
- MHLW to Run Pilot Sale of Emergency Contraceptives without Prescription
June 29, 2023
- Citizens’ Group Opposes Pilot Switch Program for Emergency Contraceptives
June 27, 2023
- Will Pilot Switch Proposal Break Stalemate in Emergency Contraceptive Debate?
June 23, 2023
- MHLW Mulls New OTC Class to Bar Online Sales amid Unease over Morning After Pills
June 14, 2023
- LDP Lawmakers Oppose Online Sale of Morning After Pills 3 Years after Switch
June 8, 2023
- MHLW Taking Public Comments on OTC Access to Emergency Contraceptives
January 6, 2023
REGULATORY
- MHLW Preparing to Submit Bill to Amend PMD Act in Mid-February
January 17, 2025
- CSL’s HAE Drug, Tecentriq Up for Panel Review on Jan. 30; 1st Cases of Expedited Approval
January 17, 2025
- Minimum NHI Prices to Be Raised by 3% Across the Board on April 1
January 16, 2025
- 3 JAK Inhibitors, Wegovy and More Drugs Enjoy First Off-Year Application of Post-Launch Premiums
January 16, 2025
- Govt Must Not Let Pro-Innovation Reform of 2024 Go to Waste: Sr Vice Minister
January 15, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…